Liver Failure, Acute on Chronic Clinical Trial
Official title:
Mesenchymal Stem Cells-Derived Extracellular Vesicles (MSC-EV) in Acute-on-Chronic Liver Failure After Liver Transplantationa:a Prospective, Randomized, Controlled Clinical Study
Verified date | October 2023 |
Source | Third Affiliated Hospital, Sun Yat-Sen University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Acute-on-chronic liver failure refers to a liver failure syndrome in which some patients with chronic liver disease with relatively stable liver function suffer from acute liver decompensation and liver failure due to the effects of various acute injury factors. Liver transplantation is the only curative treatment for this type of end-stage liver disease. The potential of MSCs to repair or regenerate damaged tissue and suppress immune responses makes them promising in the treatment of liver diseases, especially in the field of liver transplantation. Many studies have shown that MSC-based therapies can reduce the symptoms of liver disease due to their paracrine effects. Therefore, compared to the cells they derive from, mesenchymal stem cells-derived extracellular vesicles (MSC-EV) are gradually gaining attention for their enhanced safety, as they do not replicate or cause microvascular embolism, and can be easily stored without losing their properties. It represents a novel and effective cell-free therapeutic agent as alternative to cell-based therapies for liver diseases, and liver failure was also concerned. This study was designed to evaluate the safety and tolerability of MSC-EV in acute-on-chronic liver failure after liver transplantation.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | April 30, 2025 |
Est. primary completion date | September 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - aged 18-60 years; - Acute on chronic liver failure-which is characterized by acute hepatic insult manifesting as jaundice (serum total bilirubin [TBil] = 10×ULN umol/L) and coagulopathy (international normalized ratio [INR] = 1.5 or prothrombin activity < 40%), complicated within 4 weeks by ascites and/or encephalopathy as determined by physical examination, in patients with previously diagnosed or undiagnosed chronic liver disease; Requiring liver transplantation due to acute on chronic liver failure; - Obtain the patients' consent after informing patients of the purpose and method of the clinical trial; Exclusion Criteria: - Past history of malignant disease - Active uncontrolled infection; - Combined transplantation - EBV-negative; - HIV or HCV positive; - Retransplantation; |
Country | Name | City | State |
---|---|---|---|
China | Third Affiliated Hospital, Sun Yat-Sen University | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Third Affiliated Hospital, Sun Yat-Sen University |
China,
Detry O, Vandermeulen M, Delbouille MH, Somja J, Bletard N, Briquet A, Lechanteur C, Giet O, Baudoux E, Hannon M, Baron F, Beguin Y. Infusion of mesenchymal stromal cells after deceased liver transplantation: A phase I-II, open-label, clinical study. J Hepatol. 2017 Jul;67(1):47-55. doi: 10.1016/j.jhep.2017.03.001. Epub 2017 Mar 9. — View Citation
Lin BL, Chen JF, Qiu WH, Wang KW, Xie DY, Chen XY, Liu QL, Peng L, Li JG, Mei YY, Weng WZ, Peng YW, Cao HJ, Xie JQ, Xie SB, Xiang AP, Gao ZL. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial. Hepatology. 2017 Jul;66(1):209-219. doi: 10.1002/hep.29189. Epub 2017 May 27. — View Citation
Psaraki A, Ntari L, Karakostas C, Korrou-Karava D, Roubelakis MG. Extracellular vesicles derived from mesenchymal stem/stromal cells: The regenerative impact in liver diseases. Hepatology. 2022 Jun;75(6):1590-1603. doi: 10.1002/hep.32129. Epub 2021 Nov 27. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with MSC-EV infusion-related toxicity as assessed by CTCAE v4.0. | Incidence, timing and severity of any clinical complication related to MSC-EV infusion, such as tympanic body temperature, heart rate, mean arterial blood pressure and allergy, as assessed by CTCAE v4.0 . | 24 hours after injection | |
Primary | Aspartate aminotransferase (AST) | Collect clinical results reflecting liver function | 6 months after transplantation | |
Primary | Alanine aminotransferase (ALT) | Collect clinical results reflecting liver function | 6 months after transplantation | |
Primary | Bilirubin level | Collect clinical results reflecting liver function | 6 months after transplantation | |
Primary | International normalized ratio (INR) | Collect clinical results reflecting liver function | 6 months after transplantation | |
Primary | carbohydrate Compound antigen (GGT) level | Collect clinical results reflecting liver function | 6 months after transplantation | |
Primary | Adverse events | Any adverse events which may related to MSC-EV infusion | 6 months | |
Secondary | Number of survived patients at 1 year after liver transplantation, according to the follow-up results. | Patients who are surviving, as assessed by outpatient or telephone follow-up, at 1 year after liver transplantation | 12 months | |
Secondary | Number of survived grafts at 1 year after liver transplantation, according to the follow-up results. | Surviving patients with primary and functional grafts, as assessed by outpatient or telephone follow-up, at 1 year after liver transplantation. | 12 months | |
Secondary | Recipient's immune function, as assessed by analysis of immune cell subsets from biopsy or blood samples ,at months 1-6 after liver transplantation. | A series of immune cell subsets will be analyzed, including T cells (CD3+), CD4+ T cells (CD3+ CD4+ lymphocytes), CD8+ T cells (CD3+ CD8+ lymphocytes), naïve CD4+ T cells (CD4+ CD45RAhigh lymphocytes), memory CD4+ T cells (CD4+ CD45RO+ lymphocytes), natural killer (NK) cells (CD3- CD56+ lymphocytes), as well as B cells (CD19+ lymphocytes) | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05793983 -
S100A8/A9 and Innate Immunity in Liver Disease
|
||
Completed |
NCT03641872 -
A Validation Cohort for ACLF Diagnosis and Prognosis
|
||
Not yet recruiting |
NCT03863002 -
Safety and Efficacy of Mesenchymal Stem Cell Transplantation for Acute-on-Chronic Liver Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05786859 -
The Efficacy and Safety of Rifaximin Treatment
|
Early Phase 1 | |
Completed |
NCT03312036 -
HEpatic Regeneration With COupled Plasma Filtration and Adsorption for Liver Extracorporeal Detoxification
|
N/A | |
Completed |
NCT04959110 -
Citrate Pharmacokinetics in Critically Ill Liver Failure Patients Receiving CRRT
|
N/A | |
Completed |
NCT02457637 -
Chinese CLIF-C Acute-on-Chronic Liver Disease and Liver Failure Study
|
||
Completed |
NCT03281265 -
A Retrospective Multicenter Study of HBV-related Pre-acute-on-chronic Liver Failure in China
|
N/A | |
Recruiting |
NCT03281252 -
A Prospective Study of Evaluation of Minor Bleeding and Utility of Bleeding Criteria in Acute-on-chronic Liver Failure Patients in China
|
N/A |